News Headlines
-
Lonza Signs Agreement To Acquire US CDMO Network From Merck KGaA, Darmstadt, Germany, And Significantly Expands Its US Presence
11/3/2026
Lonza, the world’s leading contract development and manufacturing organization (CDMO), announced today that it has signed a definitive agreement to acquire five CDMO manufacturing sites in the US from Merck KGaA, Darmstadt, Germany at a total enterprise valuation in the low- to mid-triple-digit millions Swiss francs.
-
Global Pharmaceutical Company Commits To A Dual-Site Deal With AGC Biologics Exceeding €0.5B
11/3/2026
AGC Biologics has expanded its existing long-term manufacturing agreement with a global pharmaceutical company, adding a second supply node at the CDMO’s Copenhagen facility. The expansion, which builds on the existing agreement anchored at AGC Biologics’ Yokohama site, grows the deal’s total value beyond €0.5B.
-
Teva And Samsung Bioepis Announce Agreement To Commercialize Two FDA-Approved Biosimilars In The U.S.
11/3/2026
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Samsung Bioepis Co., Ltd. today announced that they have entered into a license and commercialization agreement for two FDA-approved immunology biosimilars: infliximab-abda, a biosimilar to Remicade®1 (infliximab) and ETICOVO® (etanercept-ykro), a biosimilar to Enbrel®2 (etanercept).
-
CStone And Kimia Therapeutics Enter Clinical Development Collaboration To Advance A Novel Drug Candidate Targeting Repair Pathways Critical For Solid Tumor Survival
11/3/2026
CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas, today announced that it has entered into a clinical collaboration agreement with Kimia Therapeutics, Inc. ("Kimia"), a biopharmaceutical company developing innovative therapeutics for oncology and immunology, to advance the clinical development of a potential first-in-class asset targeting the DNA damage response (DDR) pathway critical for solid tumor cell survival, with CStone leading the clinical development in mainland China and Australia.
-
Brise Pharmaceuticals Announces Global License Agreement With AbbVie To Advance The Next-Generation Of Migraine Therapies
11/2/2026
Brise Pharmaceuticals Co., Ltd. (Brise) today provided an update on its exclusive license agreement with AbbVie (NYSE: ABBV), which the companies entered in 2024. Under the terms of the collaboration agreement, Brise is responsible for discovery efforts and AbbVie will lead global development and commercialization activities for two of Brise's preclinical migraine programs.
-
Lynk Pharmaceuticals Announces Commercialization Collaboration With Simcere For Zemprocitinib In Dermatology Indications, Further Expanding Product Commercialization Footprint
11/2/2026
Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), today announced that it has expanded its commercialization collaboration with Simcere Pharmaceutical Group Limited ("Simcere") for zemprocitinib, a highly selective, oral, second-generation JAK1 inhibitor independently developed by Lynk Pharmaceuticals.
-
Fresenius And WuXi Biologics Enter Exclusive Development Agreement To Expand Biosimilars Pipeline
11/2/2026
Fresenius SE & Co. KGaA (XETR: FRE) (OTCM: FSNUY) today announced that it has entered an exclusive development agreement with WuXi Biologics (2269.HK), a leading global contract organization for research, development and manufacturing.
-
Novavax Earns $125M Milestone As Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial In Europe
10/29/2026
Novavax (Nasdaq: NVAX) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax's COVID-19 vaccine, Nuvaxovid™.
-
Boditech Med Partners With Biosys For Local Manufacturing In Brazil To Expand In South America
10/29/2026
Boditech Med Inc., a global provider of point-of-care diagnostic solutions, announced a strategic partnership with Biosys, a Brazilian in vitro diagnostics (IVD) company, for local manufacturing and supply.
-
Lonza Further Expands Bioconjugation Manufacturing To Support Growing ADC Demand
10/29/2026
Lonza, the world’s leading contract development and manufacturing organization (CDMO), announced today the further expansion of its integrated bioconjugation manufacturing offering. Lonza is combining the flexibility of mid-scale bioconjugation manufacturing with its previously announced large-scale bioconjugation expansion in Visp (CH), which will now include three multiproduct suites. Together, these capabilities will offer customers a scalable manufacturing pathway from clinical development through commercial supply for antibody-drug conjugates (ADCs) and other bioconjugates.